Cumulative sales of SK Biopharmaceutical’s epilepsy treatment cenobamate exceeded KRW 300 billion in the US. It had continued to show growth every quarter ever since its release. Combined with the upfront payment and milestone payments cenobamate has earned more than KRW 700 billion over the past 4 years.

According to SK Biopharm on the 11th, cenobamate posted sales of KRW 53.9 billion in the United States in Q1 last year. This is a 70.0% increase from the KRW 31.7 billion made in the same period last year. This also surpassed the previous record of KRW 49.8 billion recorded in the previous quarter by 8.2%, and the sales showed continued growth every quarter since its release.

The total num